Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Stryker (SYK) To Gain From Solid Portfolio And Acquisitions

Published 09/28/2017, 10:10 PM
Updated 07/09/2023, 06:31 AM

Stryker Corporation (NYSE:SYK) , one of the largest medical device companies in the global orthopedic market, has successfully expanded its product portfolio over time, which aids the company to cater to evolving demands of customers.

The Kalamazoo, MI-based company boasts a diverse portfolio that has been aiding top-line growth, reflected through projected revenue growth of 8.53%. We expect the momentum to continue, banking on the strength of its portfolio and acquisitions.

The company’s product portfolio cushions it against any significant sales shortfall during economic downturns. Stryker’s pipeline includes products for Hip, Knee and Mako Robotic-Arm Assisted Surgeries. MAKO results in the last quarter were solid, with almost 26 global robot installations, of which, 24 were in the United States.

Furthermore, the platforms of bone cement, sports-medicine, bones substitute, soft tissue repair, trauma and extremities, endoscopy and more fortify the company’s market position. Meanwhile, Stryker’s exclusive navigation platform provides streamlined software solutions that allow surgeons to accurately track, analyze and monitor instrumentation pertaining to a patient’s anatomy during surgical procedures to enhance patient outcomes. We expect Stryker to perform well by virtue of its strong and diverse portfolio, innovative pipeline, strategic acquisitions along with ongoing cost control measures and increasing operating efficiency.

Stryker has been following an acquisition-driven strategy to boost growth profile. The acquisition of NOVADAQ Technologies Inc completed in September is a recent example.

Stryker has been focusing on international growth as well. In particular, the company’s Medsurg product line has witnessed strong demand in the European and Australian markets in 2017. However, China might prove to be a challenging market.

On the flip side Stryker along with its peers like Orthofix International N.V. (NASDAQ:OFIX) , Female Health Company (NASDAQ:VERU) and LeMaitre Vascular, Inc (NASDAQ:LMAT) , continues to be challenged by lower demand for health care products. Additionally, the company’s spine business in the United States witnessed supply issues in 2017. The company has been facing challenging global economic conditions, particularly in the United States and Western Europe. Additionally, lower reimbursements for medical products and services may impose a downward pressure on the prices for the company’s products which will ultimately impact the top line.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.


With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>



Stryker Corporation (SYK): Free Stock Analysis Report

Orthofix International N.V. (OFIX): Free Stock Analysis Report

LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report

Female Health Company (The) (VERU): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.